Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | Filing |
| 2023-02-14 11:32 am Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | GLAZER CAPITAL LLC | 1,254,733 9.5% | 1,254,733 (New Position) | View |
| 2023-02-13 4:04 pm Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | Periscope Capital Inc. | 776,797 5.88% | 776,797 (New Position) | View |
| 2023-02-06 4:43 pm Sale | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | INTEGRATED CORE STRATEGIES (US) LLC | 793,018 6% | -19,042 (-2.34%) | View |
| 2022-02-14 06:19 am Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | CITADEL ADVISORS LLC | 625,909 4.7% | 625,909 (New Position) | View |
| 2022-02-08 4:10 pm Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | LSP Sponsor EBAC B.V. | 3,593,792 21.92% | 3,593,792 (New Position) | View |
| 2022-01-27 4:35 pm Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | INTEGRATED CORE STRATEGIES (US) LLC | 812,060 6.1% | 812,060 (New Position) | View |
| 2021-04-02 4:01 pm Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | CITADEL ADVISORS LLC | 625,093 5% | 625,093 (New Position) | View |
| 2021-03-24 4:13 pm Purchase | 13G | EUROPEAN BIOTECH ACQUISITION C EBAC | INTEGRATED CORE STRATEGIES (US) LLC | 870,000 7% | 870,000 (New Position) | View |